SRR10900012
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.300
- PANCREAS_BETA_CELLS+0.300
- HEDGEHOG_SIGNALING+0.200
- KRAS_SIGNALING_UP+0.200
- NOTCH_SIGNALING+0.200
- ANGIOGENESIS+0.100
- BILE_ACID_METABOLISM+0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.100
- KRAS_SIGNALING_DN+0.100
- MYOGENESIS+0.100
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- MYC_TARGETS_V1-0.500
- DNA_REPAIR-0.400
- E2F_TARGETS-0.400
- FATTY_ACID_METABOLISM-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- MTORC1_SIGNALING-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- ADIPOGENESIS-0.300
- G2M_CHECKPOINT-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202446 | — | — | 0.866 |
| 2 | TCGA-CF-A9FL-01A-11R-A38B-07 | — | — | 0.863 |
| 3 | SRR8942979 | — | — | 0.859 |
| 4 | SRR13311172 | — | — | 0.858 |
| 5 | MNG608 | — | — | 0.857 |
| 6 | TCGA-CR-7388-01A-11R-2016-07 | — | — | 0.855 |
| 7 | C3N-03911 | — | cohortA1 | 0.854 |
| 8 | MNG243 | — | — | 0.851 |
| 9 | TCGA-55-8096-01A-11R-2241-07 | — | cohortA1 | 0.851 |
| 10 | SRR8942991 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |